Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center

Part of paid clinical trials in Stanford, California.

Sponsor
Stanford University
Study ID
NCT01510626
Phase
PHASE1
Status
Completed

Conditions

  • Immune System Diseases

Eligibility Criteria

Sex
ALL
Age
4 Years - 55 Years
Healthy Volunteers
Not accepted

Interventions

  • Food proteins — DIETARY_SUPPLEMENT
    Food proteins
  • Omalizumab — DRUG
    Drug

Study Details

The long-term goal of the investigators study is to develop a better and safer treatment for, and to potentially cure patients with single or multiple food allergies. The investigators hypothesize that the application of this protocol will allow patients with severe and single or multiple food allergies to be safely and rapidly desensitized.

Key Dates

Start date
Nov 30, 2011
Status verified
Dec 2015
Primary completion
Apr 30, 2014
Completion
Dec 31, 2015

Study Design

Enrollment
35 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: One

Primary Outcome Measure

Number of adverse events in the treatment population [ Time Frame: 2 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford University School of MedicineStanfordCalifornia94305-

Find similar trials in Stanford, CA

By research site
Stanford University School of Medicine· Stanford, CA

Related Studies